Most of the drugs approved by the FDA for the treatment of AD are inhibitors of AchE, and their mechanism is to inhibit the activity of AchE, thereby increasing the content of ACh neurotransmitters in the brain [25]. The gene discussed is ACHE; the disease is Alzheimer disease.